Previous 10 | Next 10 |
Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer Two additional metastatic breast cancer clinical trials in progress also presented PHILADELPHIA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq:...
Context Therapeutics (CNTX +18.1%) is trading sharply higher ahead of a key data readout on the company’s ongoing clinical trials for the company’s lead asset onapristone extended-release (ONA-XR) in patients with metastatic breast cancer. As highlighted on Seeking Alpha Catalys...
PHILADELPHIA, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX) ("Context Therapeutics" or the "Company"), a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers, today announce...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Context Therapeutics (NASDAQ:CNTX): Q3 GAAP EPS of -$4.00. Cash and cash equivalents were $0.4 million at September 30, 2021 compared to $0.3 million at December 31, 2020. Press Release For further details see: Context Therapeutics reports Q3 results
Entered into $31.25 million Private Placement Agreement Completed Initial Public Offering of Common Stock and Raised $28.75 million in Gross Proceeds Dosed First Patient in Phase 2 ER+, PR+, HER2- Metastatic Breast Cancer Clinical Trial PHILADELPHIA, Dec. 02, 2021 (G...
Gainers: Biofrontera (NASDAQ:BFRI) +36%. CF Acquisition (NASDAQ:CFVIU) +19%. Day One (NASDAQ:DAWN) +16%. Terns Pharmaceuticals (NASDAQ:TERN) +15%. Duluth Holdings (NASDAQ:DLTH) +15%. Snowflake (NYSE:SNOW) +14%. Aurinia Pharmaceuticals (NASDAQ:AUPH) +14%. Express (NYSE:EXPR) +13%. Vor Biopharm...
Gainers: Biofrontera (NASDAQ:BFRI) +29%, Terns Pharmaceuticals (NASDAQ:TERN) +20%, Aurinia Pharmaceuticals (NASDAQ:AUPH) +17%, Atreca (NASDAQ:BCEL) +12%, 4D pharma (NASDAQ:LBPS) +9%. Losers: Context Therapeutics (NASDAQ:CNTX) -29%, 180 Life Sc...
Tantech Holdings (NASDAQ:TANH) -55% on pricing $13.7M stock offering. Kirkland's (NASDAQ:KIRK) -27% on Q3 earnings release. OceanPal (NASDAQ:OP) -22%. Alset EHome International (NASDAQ:AEI) -16%. 180 Life Sciences (NASDAQ:ATNF) -14%. Context Therapeutics (NASDAQ:CNTX) ...
Context Therapeutics (NASDAQ:CNTX) has entered into securities purchase agreements of 5M shares of common stock together with warrants to purchase equal number of shares, which will result in gross proceeds of ~$31.25M, in a private placement. Each share of common stock and Warrant are being ...
News, Short Squeeze, Breakout and More Instantly...
Context Therapeutics Inc. Company Name:
CNTX Stock Symbol:
NASDAQ Market:
Context Therapeutics Inc. Website:
CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the ...
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”...